Biovica International has mutually terminated its reference laboratory agreement with Tempus AI, originally announced in May 2025, as part of a refocused US commercial strategy. The collaboration, which intended to offer Biovica's DiviTum TKa test through Tempus's diagnostic portfolio to US oncologists, did not progress to a commercial launch and generated no revenue. CEO Theis Kipling stated that more than a year after the agreement was announced, it had not resulted in patient access or revenue, prompting the decision to redirect resources toward channels with a clearer path to near-term adoption. The termination does not affect Biovica's CLIA/CAP-accredited laboratory operations in San Diego, its existing US clinical activities, or its Pharma Services business. Biovica will continue to evaluate partnership opportunities to support broader adoption of DiviTum TKa in the US market.
Tempus AI, Inc. Class A Common StockTempus AI loses potential revenue from commercializing Biovica's DiviTum TKa test, though no revenue was generated.
Biovica terminates a partnership that failed to generate patient access or revenue, delaying US market adoption.